SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Grith P. Eng, Klaus Bendtzen, Henning Bliddal, Michael Stoltenberg, Marcin Szkudlarek, Viktoria Fana, Hanne M. Lindegaard, Emina Omerovic, Pil Højgaard, Elmo K. Jensen, Pierre N. Bouchelouche, Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study, Arthritis, 2015, 2015, 1

    CrossRef

  2. 2
    Eduardo Mysler, Biosimilars: Clinical Interpretation and Implications for Drug Development, Current Rheumatology Reports, 2015, 17, 2

    CrossRef

  3. 3
    Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah, David J. Harrison, Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis, Journal of Medical Economics, 2015, 18, 5, 376

    CrossRef

  4. 4
    M. Neovius, E. V. Arkema, H. Olsson, J. K. Eriksson, L. E. Kristensen, J. F. Simard, J. Askling, E. Backlund, L. Coster, H. Forsblad-d'Elia, N. Feltelius, L. Jacobsson, L. Klareskog, S. Lindblad, S. Rantapaa-Dahlqvist, T. Saxne, R. van Vollenhoven, Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab, Annals of the Rheumatic Diseases, 2015, 74, 2, 354

    CrossRef

  5. 5
    Ditza Levin, Basil Golding, Scott E. Strome, Zuben E. Sauna, Fc fusion as a platform technology: potential for modulating immunogenicity, Trends in Biotechnology, 2015, 33, 1, 27

    CrossRef

  6. 6
    Jie Zhang, Fenglong Xie, Elizabeth Delzell, Huifeng Yun, James D. Lewis, Kevin Haynes, Lang Chen, Timothy Beukelman, Kenneth G. Saag, Jeffrey R. Curtis, Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients, Arthritis Care & Research, 2015, 67, 5
  7. 7
    D.-Y. Chen, Y.-M. Chen, W.-C. Tsai, J.-C. Tseng, Y.-H. Chen, C.-W. Hsieh, W.-T. Hung, J.-L. Lan, Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis, Annals of the Rheumatic Diseases, 2015, 74, 3, e16

    CrossRef

  8. 8
    Jochen H.O. Hoffmann, Christian Knoop, Alexander H. Enk, Eva N. Hadaschik, Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: A retrospective investigation of 146 psoriasis patients, Journal of Dermatological Science, 2014, 76, 3, 180

    CrossRef

  9. 9
    J. S. Smolen, R. Landewe, F. C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. de Wit, D. Aletaha, N. Betteridge, J. W. J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. M. W. Hazes, M. Kouloumas, T. K. Kvien, X. Mariette, K. Pavelka, P. L. C. M. van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. L. Scott, T. Sokka-Isler, J. B. Wong, D. van der Heijde, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, 2014, 73, 3, 492

    CrossRef

  10. 10
    Mauro Keiserman, Catalin Codreanu, Rohini Handa, Daniel Xibillé-Friedmann, Eduardo Mysler, Francisco Briceño, Servet Akar, The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences, Expert Review of Clinical Immunology, 2014, 10, 8, 1049

    CrossRef

  11. 11
    M. Jani, A. Barton, R. B. Warren, C. E. M. Griffiths, H. Chinoy, The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases, Rheumatology, 2014, 53, 2, 213

    CrossRef

  12. 12
    Paul Chamberlain, Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations, Bioanalysis, 2013, 5, 5, 561

    CrossRef

  13. 13
    Laura Hunt, Paul Emery, Etanercept in the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 2013, 13, 10, 1441

    CrossRef

  14. 14
    J.M. Carrascosa, Immunogenicity in Biologic Therapy: Implications for Dermatology, Actas Dermo-Sifiliográficas (English Edition), 2013, 104, 6, 471

    CrossRef

  15. 15
    J.M. Carrascosa, Inmunogenicidad en terapia biológica. Implicaciones en Dermatología, Actas Dermo-Sifiliográficas, 2013, 104, 6, 471

    CrossRef

  16. 16
    Marc Cohen, Mohammed A Omair, Edward C Keystone, Monoclonal antibodies in rheumatoid arthritis, International Journal of Clinical Rheumatology, 2013, 8, 5, 541

    CrossRef

  17. 17
    Iris Navarro-Millán, Jeffrey R. Curtis, Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis, Current Opinion in Rheumatology, 2013, 25, 3, 384

    CrossRef

  18. 18
    Janice M. Reichert, Adalimumab (Humira®),